Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

Solabegron demonstrates efficacy in phase II study

Feb. 28, 2012

Long-term and post hoc phase III data presented on mirabegron

Feb. 28, 2012

Resiniferatoxin improves urodynamic parameters in patients with overactive bladder

Feb. 28, 2012

Merck & Co. patents novel beta3-adrenoceptor agonists

Feb. 23, 2012

Preparations begin for European trial of NX-1207

Feb. 22, 2012

Ongoing phase III trials of NX-1207 show no safety concerns

Feb. 17, 2012

German marketing collaboration signed for Vitaros

Feb. 17, 2012

Nippon Chemiphar patents new candidate therapies for urinary incontinence

Feb. 15, 2012

New E-NPP 2 inhibitors patented by Ono Pharmaceutical

Feb. 10, 2012

Recordati presents new metabotropic glutamate mGlu5 receptor antagonists

Feb. 9, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...